Plain-English translation of NCT06333483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new therapy called for people with severe lupus that hasn't improved with standard medicines. The treatment works by using your own immune cells, which are collected, specially modified in a lab, and then returned to your body to help control the lupus. Researchers want to understand how safe this treatment is and whether it helps reduce lupus symptoms.
Severe lupus can cause serious damage to organs and severely impact quality of life, and many patients don't improve enough with existing treatments. This trial exists to explore whether this new cell-based approach might offer hope for people whose lupus has resisted other therapies.
If you join this trial, you will undergo a screening period to make sure the treatment is safe for you, followed by collection of your immune cells through a procedure called leukapheresis. Your cells will be sent to a laboratory to be modified, and then you will receive the modified cells back into your body as an infusion. You will then be monitored closely during follow-up visits to check for safety, side effects, and whether the treatment is helping your lupus improve.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Spain
United Kingdom